Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
A great group of Doctors that believe in this incredible product!
New York City, Feb 12, 2019 (Issuewire.com) - Dr. Abate completed his undergraduate degree from Fairleigh Dickinson University in New Jersey where he graduated with his Bachelor of Science. Wanting to further his education he completed his Medical Degree from the Universidad Central del Este in the Dominican Republic in 1981, giving him over three decades of experience in his field. After completing his Medical Degree he returned to the United States and completed his internal medicine internal medicine residency with the St. Vincent’s Medical Center. Wanting to further his training he then completed his cardiology fellowship with the University of South Florida.
Dr. Abate is a leader in pharma and diagnostics industries. He currently practices as a consultant in Medical Affairs, Clinical Development, and Pharmacovigilance with Vite-Scientia Consulting. He has experience in instituting the processes and controls needed to protect financial integrity and manage risks, yielding impressive results in both top-line and bottom-line efficiencies. He is an expert developer of high-performance cultures with a demonstrable capacity in navigating positive change management while addressing mission-critical business needs. He holds expertise in selecting, training and developing top-performing executive talent across multifaceted capacities with verifiable success in the architecture and management of globally-scaled businesses.
Dr. John Conrad, MD
Vascular Surgeon
Burbank, CA
Dr. John Conrad, MD is a Vascular Surgeon in Burbank, CA. Dr. Conrad completed their Medical School at University Of California. Following their education, Dr. Conrad was board certified by the American Board of Surgery.…read less
Are you Dr. Conrad, MD?Claim your profile
Specialties
Vascular Surgeon
Hospital affiliations
Encino Hospital Medical Center
Glendale Adventist Medical Center
Providence St. Joseph Medical Center
Sherman Oaks Hospital
Simi Valley Hospital
Board certifications
American Board of Surgery Certification in Surgery
American Board of Vascular Surgery Certification in Vascular Surgery
Education and training
Baylor University Medical Center (Residency)
University Of California (Medical School)
Dr. Sasan Najibi, MD
Vascular Surgeon
Tarzana, CA
Dr. Sasan Najibi, MD is a Vascular Surgeon in Tarzana, CA. Dr. Najibi completed their Residency at University Of Fl College Of Medicine. Following their education, Dr. Najibi was board certified by the American Board of Surgery.…read less
Are you Dr. Najibi, MD?Claim your profile
Specialties
Vascular Surgeon
Hospital affiliations
Encino Hospital Medical Center
Glendale Adventist Medical Center
Providence St. Joseph Medical Center
Providence Tarzana Medical Center
Sherman Oaks Hospital
Simi Valley Hospital
Board certifications
American Board of Surgery Certification in Surgery
American Board of Vascular Surgery Certification in Vascular Surgery
Education and training
University Of California (Medical School)
University Of Fl College Of Medicine (Residency)
Dr. Raymond Schaerf, MD
Cardiothoracic Surgeon
Burbank, CA
Dr. Raymond Schaerf, MD is a Cardiothoracic Surgeon in Burbank, CA. Dr. Schaerf completed their Residency at University Miami/Jackson Mem Mc. Following their education, Dr. Schaerf was board certified by the American Board of Thoracic and Cardiac Surgery.…read less
Are you Dr. Schaerf, MD?Claim your profile
Specialties
Cardiothoracic Surgeon
Hospital affiliations
Cedars-Sinai Medical Center
Providence St. Joseph Medical Center
Providence Tarzana Medical Center
Board certifications
American Board of Thoracic and Cardiac Surgery Certification in Thoracic and Cardiac Surgery
Education and training
New York Medical College (Medical School)
University Miami/Jackson Mem Mc (Residency)
I’m with you!
Love this stock and company!
rodman are you ok?
We all in this conversation want Ueec to go higher
I hope you have better days ahead
Thank you DrStonks
If Rodman read the article carefully or just brush over he would see it is very positive!
I thought after being attacked I read it wrong. So... I read it again and had others read it and they all thought it was just a description of the results of the process for approval.
My conclusion was that Ueec is on the right track with a great product and has a very high likelihood of getting approval. I am long and still own almost million shares!
Go Ueec
Article was not positive my bad!
I must have read it wrong sorry!
Thought it said if we got this far we are huge favorite to be cleared by FDA
I own almost 1 mill shares for years...
Oops
Great article! A must read for all longs and shorts of UEEC!
I am long and strong!
Thank you!
Totally agree!
Anyone accepting side bets on Ueec? Over under on PPS?
By September 2020? Like meet and bye a cup of coffee?
Totally agree... Thank you...I believe the product works and should pass with flying colors...
Completely understand everyones feelings...I enjoy all the posts... educates and passes the time waiting for what I trust can happen with our investment in UEEC...The well thought out factual responses in each discussion has so much value... from a reminder of all things we know to new knowledge, evidence in court case, new ways to look at negatives and positives concerning UEEC...everyone keep posting please... if you are like me I try to digest everything I can and look forward to the education and editorials on UEEC... So when you have the urge let it rip!
I disagree Chrism0000
I like all angles on UEEC
Is Dr A Alwaysintheknow?
Great post thank you!Could the peer review paper play also as advertisement (exposure)for purchasing company so they hit the ground running like moving the Manufacturing to Westminster Maryland?
Thinking about what UEEC I has announced?
Moving manufacturing to US
Located in Westminster Maryland
Has....
HENDERSON, Nev., Oct. 17, 2019 (GLOBE NEWSWIRE) -- United Health Products, Inc. (UEEC), (“UHP” or the “Company”), developer, manufacturer and marketer of HemoStyp®, an Oxidized Regenerated Cellulose gauze, today announced that it will relocate the majority of its manufacturing operations to a United States facility. UHP is recently partnering with an established contract manufacturing company and is leasing “clean room” space at the partner’s state-of-the-art facility in the Baltimore suburb of Westminster, Maryland. The facility is ISO 9001 and 13485 certified, and offers certain engineering and technical services that will help UHP rapidly increase production of existing and new HemoStyp formats, in anticipation of a successful FDA Class III PMA application approval, the potential acquisition of the Company or a strategic partnership. Once fully operational, the facility will be capable of manufacturing up to 20 million square inches of HemoStyp gauze monthly. Additional formulations of the HemoStyp product designed for the specialized human surgical market will also be produced at this facility. UHP is onshoring its production operations to improve its order response time, reduce freight costs and improve scalability.
That seems to point to......
https://www.strouse.com/blog/2014/01/14/strouse-cleanroom-iso-7-certified
Anyone else find this interesting?
Thanks!
LOL
I appreciate the quick response
I was not trying to draw you in...
Just get the other angle of this equation...
A few of your points I have lived in another drug company investment
FDA cleared but is unable to get fully into its market.
A product needs more than clearance.
Lots of obstacles other than FDA!
Changing culture of Purchaser and Doctors...
I would still love to hear your thoughts on the future if this goes along the plans of us longs!
Thanks
Chop
Sir, In your opinion what would a patented formula for production of a industry leading product be worth?
Depends on market I guess?
Depends on profit margin?
Distribution capabilities?
Facilities already in place?
So if you were in that business and about to get better product or protect your current market could be
worth...X
So let’s see...
All the Longs believe it is a remarkable industry leading product for someone out there.
I would love to hear your estimate on this assuming UEEC Executes?
Thanks for your time to calculate and response!
Sincerely
Got 20k shares more at about 1.08 avg.
Love the news
Feels like a Short attack! I’m buying on way down! Thank you! More dry powder in great place!
I would think that all the competitors are making offers. Which is real good for all of us Longs!
Bored waiting for news so I guess he is a good distraction and laugh...
Also get few a buying opportunities
I will buy on any down turn... anyone who wants to keep giving us opportunities?
Thank you!
Pretty good for a P.O. Box!
Read it and weep shorts!
HOW TO USE A HEMOSTATIC GAUZE PRODUCT TO HELP CONTROL BLEEDING IN CLINICAL SETTINGS
David Ramey, DVM, Margaret Mudge, DVM, DACVS
INTRODUCTION
Trauma, as well as a variety of equine surgical procedures, may occasionally result in large amounts of frank hemorrhage in the horse. Simple wounds may lacerate large vessels, routine surgical procedures such as castrations may result in excessive bleeding, and debridement of granulation tissue or surgeries of areas such as the equine sinus may result in persistent hemorrhage. Controlling such bleeding can sometimes be challenging. Furthermore, excessive bleeding may be of great concern to horse owners. As such, there may be occasions where a hemostatic agent may be of use in clinical equine medicine and surgery.
In human medicine, topical hemostatic agents are desirable and sometimes necessary to facilitate the process of hemostasis Many different types of effective hemostatic agents have been invented in the past century.1, 2, 3 The choice of a hemostatic agent in humans medicine is made in light of a number of factors, including safety, affordability, efficacy, ease of use, and the condition being treated.
Topical agents have been used to facilitate hemostasis for thousands of years but remained largely ineffective in practice until the past century.4 Advances in hemostatic technology have led to an assortment of products that are all capable of controlling bleeding and are used in wound care, dentistry, and surgery.5 Topical hemostatic agents are invaluable in surgery to control bleeding when conventional hemostatic methods such as ligature or cauterization are impractical or ineffective. They were used in approximately 30% of human surgical procedures in 2010.6
Recently, an absorbable hemostatic gauze (AHG) has been introduced into the human market.a The gauze product is registered with the United State Food and Drug Administration (USFDA) to control bleeding in open wounds and in body cavities. It is an approved Class II medical device and it is currently enrolled in the FDA’s pre-market approval (PMA) program awaiting Class III approval, which would allow the product to be used for intraoperative bleeding in the United States. It recently obtained Class III and CE mark approval in the European Economic Area (EEA) and is now approved for use in internal surgical procedures in over 30 countries. The authors have used this product on a variety of clinical equine cases and have found it to be a safe and effective way to assist in controlling hemorrhage in horses.
MATERIALS AND METHODS
The AHG agent used in this study comes in a sterile packet and various sizes are available. The AHG was placed on a variety of different bleeding areas, in both field and hospital setting, and compressed with mild pressure. The maximum hemostatic effect was achieved when enough AHG was used to become saturated with blood, at which point it turned into a gel. The AHG
______________________________________________________________________________
a Hemostyp®, United Health Care Products, 1225 Vista Del Monte Drive, Mesquite, NV 89027
was cut or folded as necessary depending on the severity of the hemorrhage. Any excess AHG not transformed into gel was removed. The remaining AHG was washed away with saline or left in the wound to be absorbed by the horse’s body. Wounds received post-operative care as deemed necessary by the attending veterinarian(s).
RESULTS (cases)
DISCUSSION
The AHG used in the cases is made from oxidized regenerated cellulose (ORC). Cellulose is an important cellular structural component found in virtually all plant matter, making it the most abundant organic polymer on Earth.7 The product is obtained from cotton and contains no chemicals, thrombin, or animal by-products; however, the product is chemically treated to make it bioabsorbable as oxidized derivatized esterified cellulose. It is a sterile, woven, pH neutral gauze that is hypoallergenic and 100% water soluble. The ready availability of the component ingredient makes the one used in this study to be one of the least expensive absorbable hemostatic agents available. ?
In human medicine, ORC hemostats have been in use since at least 1945.8 Their safety is evidenced by the limited number of adverse events reported in the literature and to the FDA (June 3, 2002 FDA memorandum). ORC has been used in a variety of surgeries in human medicine, including neurosurgery, orthopedic surgery, gynecologic surgery, anorectal surgery, thoracic surgery, abdominal surgery, head and neck surgery, pelvic surgery, and skin and subcutaneous procedures.9
Blood platelets become activated after an injury is suffered and release chemicals that promote adhesion of the platelets. This adhesion is indiscriminate, and clots can adhere not only to blood vessel linings, but also to collagen, glass, metal, fabric, and each other. Thus, the AHG fabric increases platelet adhesion, promoting clotting at the wound site.
As the AHG product absorbs blood, it also absorbs water from blood, making it viscous and slower moving; this helps minimize blood loss. As it absorbs blood and water, the AHG product also expands. The expanded product entraps fluid, blood proteins, platelets, and cells, essentially providing a scaffold for the natural clotting process while simultaneously plugging the wound as it turns into a gel. The AHG product thus creates an artificial clot that also helps facilitate the natural blood clotting process. In addition, the negatively charged surface of the AHG helps activate platelet factor XII to its enzyme form, which is required to initiate the intrinsic clotting pathway.
The AHG product does not have to be removed after use. The product dissolves into glucose and saline which is easily absorbed within two weeks.10,11,12 Since the product does not have to be removed, it obviates problem with bleeding after removal that can occur when gauze or other material is used to apply pressure to a wound.
Clinical research has demonstrated that the AHG product used in this study is both safe and effective, for example, it has been tested in a porcine femoral artery laceration model. It is as effective or more effective than currently available products. The product is currently approved for external use in the United States and Europe, is approved for internal use in Europe, and is currently in the pre-market approval program awaiting class III approval in the United States, which will allow the product to be used for intraoperative bleeding.
In human medicine, ORC dressings are viewed as a critical tool for clinicians to help manage a variety of wounds.13 In a clinical setting in horses, the AHG product has been shown to rapidly and effectively control and stop bleeding, safely and quickly biodegrade, with no demonstrable reaction from the horse’s body. The AHG product used in these cases was effective, easy to use, relatively inexpensive, safe, pH neutral, biocompatible, and rapidly absorbed. There was no evidence of adverse reaction to the product. Equine clinicians may want to consider such an agent for field or surgical use to help control hemorrhage.
ACKNOWLEDGEMENTS
HemoStyp® hemostatic gauze used in clinical cases was provided courtesy of United Health Care Products, 1225 Vista Del Monte Drive, Mesquite, NV 89027
David Ramey, DVM, is a member of the medical advisory board of United Health Products since 2018 and works as a consultant for the company.
REFERENCES
1. Gabay 2006; Absorbabnle hemostatic agents. Gabay M. Am J Health Syst Pharm. 2006 Jul 1;63(13):1244-53
2. Samudrala 2008; Topical hemostatic agents in surgery: a surgeon's perspective. Samudrala S.; AORN J. 2008 Sep;88(3): S2-11
3. Tomizawa 2005; Clinical benefits and risk analysis of topical hemostats: a review. Tomizawa Y. J Artif Organs. 2005;8(3):137-42.).
4. Achneck HE, Sileshi B, Jamiolkowski RM. et al. Comprehensive review of topical hemostatic agents’ efficacy and recommendations for use. Ann Surg 2010; 251: 217-228.
5. Boucher BA, Traub O. Achieving hemostasis in the surgical field. Pharmacotherapy. 2009;29(7 Pt 2):2S-7S.
6. Wright JD, Ananth CV, Lewin SN, et al. Patterns of use of hemostatic agents in patients undergoing major surgery. J Surg Res. 2014;186(1): 458–466.
7. Domb, AJ, Kost J, Wiseman DM. (eds.) Handbook of biodegradable polymers. In Stilwell RL, Marks MG, Saferstein L, Wiseman DM. Oxidized cellulose: Chemistry, processing and medical application (pp. 296–311); CRC press, 1997.
8. Frantz, VK, Lattes, R. Oxidized Cellulose – Absorbable Gauze. JAMA 1945; 129(12): 798 – 801. Available on-line at https://jamanetwork.com/journals/jama/article-abstract/276553 (Accessed February 3, 2019)
9. Emilia, M, Luca, S, Francesca, B, et al. Topical Hemostatic Agents in Surgical Practicie. Transfus Apher Sci. 2011; 45(3):305-11.
10. Dimitrijevich SD, Tatarko M, Gracy RW. Biodegradation of oxidized regenerated cellulose. Carbohydr Res 1990; 195: 247-56.
11. Dimitrijevich SD, Tatarko M, Gracv RW. et al. In vivo degradation of oxidized, regenerated cellulose. Carbohydr Res 1990; 198: 331-41.
12. Wu Y, He J, Cheng W, et al. Oxidized regenerated cellulose-based hemostat with microscopically gradient structure. Carbohydr Polym 2012; 88: 1023-1032. Available on-line at http://composites.utk.edu/papers%20in%20pdf/1-s2.0-S0144861712000781-main.pdf Accessed February 3, 2019.
13. Wu, S, Applewhite, AJ, Niezgoda, J, et al. Oxidized Regenerated Cellulose/Collagen Dressings: Review of Evidence and Recommendations. Adv Skin Wound Care. 2017 Nov; 30(11 Suppl 1): S1–S18. Available on-line at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5704727/ Accessed February 3, 2019.
NEED TO FIND THIS!
few adverse events being reported to the FDA.13 FDA memorandum June 3, 2002
Does anyone have copy of this Paper? The Company announced that a member of its Medical Advisory team Dr. David Ramey, DVM, along with his colleague Margaret Mudge, DVM, DACVS, have been informedtheir abstract titled HOW TO USE A HEMOSTATIC GAUZE PRODUCT TO HELP CONTROL BLEEDING IN CLINICAL SETTINGS has been accepted and will be published in theJournal of Veterinary Emergency and Critical Care. Dr. Ramey will be presentingthis paper at the IVECCS 2019 (i.e. International Veterinary Emergency andCritical Care) conference in Washington, DC on Saturday September 7, 2019.
Another page https://www.rameyequine.com/
From Dr. David Ramey web site!
https://www.rameyequine.com/news
Hit link and check out top item!
Let’s see FDA allows start of class 3 approval surgeries!
1. Basic surgeries with follow up check
Next
2. Moderate risk surgeries and follow up check
Next
3. High risk surgeries and follow up check
Study never stopped by Hospitals Surgeons or FDA check
Company announces completion and submission check
Seems to me things are going very well check
A product that can save lives and belongs in every
First aid kit, car, home and school!
CHECK MATE
Added 15k shares today thank you lizards
Thank you very much... we have a winner... we will see where we end up...
Thank you for the Meat and Potatoes! With the development of the suite of surgical products, bandages, and other uses. Any idea the profit margins in the industry on these items? Gauze market seems to be projected at In February 2018, the Company completed and submitted to the FDA all materialsrelevant for the pre-market approval ("PMA") for HemoStyp as a Class IIIapplication for internal surgical procedures. The 2017 U.S. market forhemostatic products used in internal surgery procedures is estimated at inexcess of US$7 billion, of which the market for ORC or similar mechanicalhemostatic products is estimated to be US$3.38 billion. This market is expectedto grow at 6.2% annually to reach $4.57 billion by 2023 (source: October 2018Market Data Forecast).
With that market alone and capturing J and J portion ((60%) that could be significant number to bottom line for acquiring company! I’m just trying to wrap my arms around markets and profit projections to estimate possible buy out price. Fun exercise when you know the products are going to be ground breaking!
Thanks in advance for work or steering to help find facts!
Has anyone done any research on the size of the Gauze market and now the size of the Surgicel and Surgifoam market?
In Philadelphia with team...
Reading IHub everyday and watching all the developments
Keep my Actipatch with me wherever we go in case some pain pops up!
Works great for me!
Thanks guys for clearing that up because I was getting odd vibe from that exchange.
Very nice!
Someone mentioned I posted on Twitter about back pain but no mention of Actipatch
That post was about a friend not me in pain.